Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-25T09:13:59.787Z Has data issue: false hasContentIssue false
  • English
  • Français

Sight and Insight: Brain Dopamine Receptor Occupancy by Neuroleptics Visualised in Living Schizophrenic Patients by Positron Emission Tomography

Published online by Cambridge University Press:  02 January 2018

John L. Waddington
John L. Waddington*
Affiliation:
Royal College of Surgeons in Ireland, St Stephen's Green, Dublin 2, Ireland
Get access Rights & Permissions [Opens in a new window]

Extract

There can be few more impressive sights in contemporary neuroscience and biological psychiatry than the imaging of neurotransmitter receptors in the brains of living human subjects by positron emission tomography (PET; Sedvall et al, 1986). How has such technology advanced our understanding of the pathophysiology and/or treatment of major psychiatric disorders?

Type
Annotation
Information
The British Journal of Psychiatry , Volume 154 , Issue 4 , April 1989 , pp. 433 - 436
Copyright
Copyright © Royal College of Psychiatrists, 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Crawley, J. C., Crow, T. J., Johnstone, E. C., et al (1986) Dopamine D-2 receptors in schizophrenia studied in vivo. Lancet, ii, 224–225.Google Scholar
Crow, T. J. (1987) The dopamine hypothesis survives, but there must be a way ahead. British Journal of Psychiatry, 151, 460–465.Google Scholar
Czudek, C. & Reynolds, G. P. (1988) Binding of 3H-SCH 23390 to post-mortem brain tissue in schizophrenia. British Journal of Pharmacology, 93 (Suppl.), 166P.Google Scholar
Dinan, T. G. (1987) Calcium-activated potassium conductance: an alternative to the dopamine hypothesis of neuroleptic action? British Journal of Psychiatry, 151, 445–459.Google Scholar
Farde, L., Wiesel, F.-A., Hall, H., et al (1987a) No D-2 receptor increase in PET study of schizophrenia. Archives of General Psychiatry, 44, 671–672.Google Scholar
Farde, L., Halldin, C., Stone-Elander, S., et al (1987b) PET analysis of human dopamine receptor subtypes using “C-SCH 23390 and 11C-raclopride. Psychopharmacology, 92, 278–284.Google Scholar
Farde, L., Wiesel, F.-A., Halldin, C., et al (1988a) Central D-2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry, 45, 71–76.CrossRefGoogle Scholar
Farde, L., Pauli, S., Hall, H., et al (1988b) Stereoselective binding of 11C-raclopride in living human brain: a search for extrastriatal central D-2 dopamine receptors by PET. Psychopharmacology, 94, 471–478.Google Scholar
Farde, L., Wiesel, F.-A., Jansson, P., et al (1988c) An open label trial of raclopride in acute schizophrenia: confirmation of D-2 dopamine receptor occupancy by PET. Psychopharmacology, 94, 1–7.Google Scholar
Hall, H., Farde, L. & Sedvall, G. (1988) Human dopamine receptor subtypes – in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride. Journal of Neural Transmission, 73, 7–21.Google Scholar
Hess, E. J., Bracha, H. S., Kleinmann, J. E., et al (1987) Dopamine receptor subtype imbalance in schizophrenia. Life Sciences, 40, 1487–1497.Google Scholar
Iversen, L. L. (1987) Commentary on Dinan's hypothesis. British Journal of Psychiatry, 151, 459–460.Google Scholar
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.Google Scholar
Köhler, C. & Radesäter, A. C. (1986) Autoradiographic visualisation of dopamine D-2 receptors in the monkey brain using the selective benzamide drug 3H-raclopride. Neuroscience Letters, 66, 85–90.Google Scholar
McKenna, P. J. (1987) Pathology, phenomenology and the dopamine hypothesis of schizophrenia. British Journal of Psychiatry, 151, 288–301.Google Scholar
O'Boyle, K. M., Molloy, A. G., Mashurano, M., et al (1986) Structural analogues of SCH 23390 as discriminators of dopamine receptor subtypes. Psychopharmacology Bulletin, 22, 599–604.Google Scholar
O'Boyle, K. M., & Waddington, J. L. (1987) 3H-SCH 23390 binding to D-1 dopamine receptors in human brain. Biogenic Amines, 4, 365–370.Google Scholar
Perlmutter, J. S., Kilbourn, M. R., Raichle, M. E., et al (1987) MPTP-induced up-regulation of in vivo dopaminergic radioligand binding in humans. Neurology, 37, 1575–1579.CrossRefGoogle ScholarPubMed
Sedvall, G., Farde, L., Persson, A., et al (1986) Imaging of neurotransmitter receptors in the living human brain. Archives of General Psychiatry, 43, 995–1005.Google Scholar
Seeman, P. (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1, 133–152.CrossRefGoogle ScholarPubMed
Seeman, P., Farde, L., Sedvall, G., et al (1988) Brain dopamine receptors in schizophrenia: PET problems. Archives of General Psychiatry, 45, 598–600.Google Scholar
Smith, M., Wolf, A. P., Brodie, J. D., et al (1988) Serial 18F-N-methyl-spiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biological Psychiatry, 23, 653–663.Google Scholar
Waddington, J. L. (1984) Tardive dyskinesia: a critical re-evaluation of the causal role of neuroleptics and of the dopamine receptor supersensitivity hypothesis. In Recent Research in Neurology (eds Callaghan, N. & Garvin, R.). London: Pitman.Google Scholar
Waddington, J. L. (1985) Further anomalies in the dopamine receptor supersensitivity hypothesis of tardive dyskinesia. Trends in Neurosciences, 8, 200.Google Scholar
Waddington, J. L. (1987) Tardive dyskinesia in schizophrenia and other disorders: associations with ageing, cognitive dysfunction and structural brain pathology in relation to neuroleptic exposure. Human Psychopharmacology, 2, 11–22.Google Scholar
Waddington, J. L. (1988a) The ageing brain, neuroleptic drugs and the enigma of schizophrenia. Irish Journal of Medical Science, 157, 135–141.Google Scholar
Waddington, J. L. (1988b) Therapeutic potential of selective D-l dopamine receptor agonists and antagonists in psychiatry and neurology. General Pharmacology, 19, 55–60.CrossRefGoogle Scholar
Waddington, J. L. & O'Boyle, K. M. (1987) The D-l dopamine receptor and the search for its functional role: from neurochemistry to behaviour. Reviews in the Neurosciences, 1, 157–184.Google Scholar
Wong, D. F., Wagner, H. N., Tune, L. E., et al (1986) Positron emission tomography reveals elevated D-2 dopamine receptors in drug-naive schizophrenics. Science, 234, 1558–1563.Google Scholar
Wyatt, R. J., Alexander, R. C., Egan, M. F., et al (1988) Schizophrenia, just the facts: what do we know, how well do we know it? Schizophrenia Research, 1, 3–18.Google Scholar
Zeeberg, B. R., Gibson, R. E., Reba, R. C., et al (1988) Elevated D-2 dopamine receptors in drug-naive schizophrenics. Science, 239, 789–791.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.